Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors

被引:3
作者
Kurnikova, Elena [1 ]
Trakhtman, Pavel [1 ]
Balashov, Dmitry [2 ]
Garloeva, Juliya [1 ]
Kumukova, Irina [1 ]
Khismatullina, Rimma [2 ]
Pershin, Dmitriy [3 ]
Shelikhova, Larisa [2 ]
Novichkova, Galina [2 ]
Maschan, Alexey [2 ]
机构
[1] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol, Transfus Med Serv, Moscow, Russia
[2] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Dept Hematopoiet Stem Cell Transplantat, Moscow, Russia
[3] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Transplantat Immunol & Immunotherapy Lab, Moscow, Russia
关键词
allogeneic healthy donor; apheresis; plerixafor; stem cell mobilization; PLUS G-CSF; INTRAVENOUS PLERIXAFOR; MOBILIZATION; AMD3100; TRANSPLANTS; ANTAGONIST; LYMPHOMA; RECEPTOR; GRAFT;
D O I
10.1111/vox.13266
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives Implementation of the technique of immunomagnetic selection requires the procurement of a large number of CD34+ cells from haploidentical donors within a single apheresis procedure. The release of stem cells with granulocyte colony-stimulating factor (G-CSF) alone is unsatisfactory in a number of donors, and plerixafor, a CXCR4 chemokine receptor antagonist, could be used as an additional mobilization agent. The aim of our study was to examine whether a lower dose of plerixafor (0.12 mg/kg) can provide sufficient increase in CD34+ cells in the peripheral blood of allogeneic healthy donors in comparison with a historical control group. In addition, we assessed the risk of inability to provide the recipient with a transplant containing the optimal dose of 8-10 x 10(6) CD34+ cells/kg body weight of the recipient. Materials and Methods In a prospective, single-arm study, we examined the results of 105 mobilizations in healthy adult haploidentical donors with G-CSF and plerixafor at a dose of 0.12 mg/kg. The historical control group consisted of 106 mobilizations with G-CSF and plerixafor at 0.24 mg/kg. Results The median increase in the number of CD34+ cells from day 4 to day 5 of mobilization was 69 cells/mu l (range, 28-240) versus 77 cells/mu l (24-217) in the groups of 0.12 and 0.24 mg/kg of plerixafor, respectively (p-value 0.255). The apheresis products contained a median of 14.4 x 10(6)/kg recipient body weight CD34+ cells versus 12.9 x 10(6)/kg in the groups that received 0.12 and 0.24 mg/kg of plerixafor, respectively (p-value 0.118). The obtained differences were not significant, which means the application of a decreased dose of plerixafor did not affect the results of mobilization. Conclusion The obtained differences in collection were not significant, and thus the application of a decreased dose of plerixafor did not affect the results of mobilization.
引用
收藏
页码:853 / 861
页数:9
相关论文
共 25 条
[1]   Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results [J].
Boulad, Farid ;
Shore, Tsiporah ;
van Besien, Koen ;
Minniti, Caterina ;
Barbu-Stevanovic, Mihaela ;
Fedus, Sylvie Wiener ;
Perna, Fabiana ;
Greenberg, June ;
Guarneri, Danielle ;
Nandi, Vijay ;
Mauguen, Audrey ;
Yazdanbakhsh, Karina ;
Sadelain, Michel ;
Shi, Patricia A. .
HAEMATOLOGICA, 2018, 103 (05) :770-777
[2]   AMD3100 plus G-CSF can successfully mobilize CD34+cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data [J].
Calandra, G. ;
McCarty, J. ;
McGuirk, J. ;
Tricot, G. ;
Crocker, S-A ;
Badel, K. ;
Grove, B. ;
Dye, A. ;
Bridger, G. .
BONE MARROW TRANSPLANTATION, 2008, 41 (04) :331-338
[3]   Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection [J].
Cashen, Amanda F. ;
Rettig, Michael ;
Gao, Feng ;
Smith, Angela ;
Abboud, Camille ;
Stockerl-Goldstein, Keith ;
Vij, Ravi ;
Uy, Geoffrey ;
Westervelt, Peter ;
DiPersio, John .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (08) :1282-1289
[4]   Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH) [J].
Cid, Joan ;
Monsalvo, Silvia ;
Castillo, Carlos ;
Pascual, Cristina ;
Moreno-Jim, Gemma ;
Lopez-Parra, Miriam ;
Andon, Concepcion ;
Guerra, Luisa ;
Esquirol, Albert ;
Sanchez-Ortega, Isabel ;
Ortega, Sandra ;
Zalba, Saioa ;
Martinez, Carmen ;
Rovira, Montserrat ;
Marin, Pedro ;
Lozano, Miquel .
TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (02)
[5]   Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction [J].
Devine, Steven M. ;
Vij, Ravi ;
Rettig, Michael ;
Todt, Laura ;
McGlauchlen, Kiley ;
Fisher, Nicholas ;
Devine, Hollie ;
Link, Daniel C. ;
Calandra, Gary ;
Bridger, Gary ;
Westervelt, Peter ;
DiPersio, John F. .
BLOOD, 2008, 112 (04) :990-998
[6]   Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma [J].
DiPersio, John F. ;
Stadtmauer, Edward A. ;
Nademanee, Auayporn ;
Micallef, Ivana N. M. ;
Stiff, Patrick J. ;
Kaufman, Jonathan L. ;
Maziarz, Richard T. ;
Hosing, Chitra ;
Frueehauf, Stefan ;
Horwitz, Mitchell ;
Cooper, Dennis ;
Bridger, Gary ;
Calandra, Gary .
BLOOD, 2009, 113 (23) :5720-5726
[7]   The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone [J].
Flomenberg, N ;
Devine, SM ;
DiPersio, JF ;
Liesveld, JL ;
McCarty, JM ;
Rowley, SD ;
Vesole, DH ;
Badel, K ;
Calandra, G .
BLOOD, 2005, 106 (05) :1867-1874
[8]   Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation [J].
Gattillo, Salvatore ;
Marktel, Sarah ;
Rizzo, Lorenzo ;
Malato, Simona ;
Malabarba, Lucia ;
Coppola, Milena ;
Assanelli, Andrea ;
Milani, Raffaella ;
De Freitas, Tiago ;
Corti, Consuelo ;
Bellio, Laura ;
Ciceri, Fabio .
TRANSFUSION, 2015, 55 (08) :1993-2000
[9]   Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study [J].
Gutierrez-Aguirre, Cesar Homero ;
Alvarado-Navarro, Dalila Marisol ;
Palomares-Leal, Alain ;
Mejia-Jaramillo, Gerardo ;
Salazar-Riojas, Rosario ;
Gomez-De Leon, Andres ;
Colunga-Pedraza, Perla Rocio ;
Sotomayor-Duque, Guillermo ;
Jaime-Perez, Jose Carlos ;
Cantu-Rodriguez, Olga Graciela ;
del Carmen Tarin-Arzaga, Luz ;
Flores-Jimenez, Juan Antonio ;
Gomez-Almaguer, David .
TRANSFUSION, 2019, :3721-3726
[10]   Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers [J].
Hendrix, CW ;
Flexner, C ;
MacFarland, RT ;
Giandomenico, C ;
Fuchs, EJ ;
Redpath, E ;
Bridger, G ;
Henson, GW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1667-1673